Work

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Year: 2014

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-14-0265

Authors: Robin L. Jones, Edward S. Kim, Pilar Nava-Parada, Salma Alam, Faye M. Johnson, Andrew W. Stephens, Ronit Simantov, Srinivasu Poondru, Rich Gedrich, Scott M. Lippman, Stan B. Kaye, Craig P. Carden

Institutions: University of Washington, Royal Marsden Hospital, Carolinas Healthcare System, Levine Cancer Institute, Celgene (United States), The University of Texas MD Anderson Cancer Center, Piramal (Germany), Astellas Pharma (United States), University of California San Diego, Moores Cancer Center

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2140498074

FWCI: 12.01

Cites: 19

Cited by: 97

Related to: 10